CLAIMS

1. Use of an effective amount of an antibody and methotrexate in the manufacture of a medicament for a concurrent or sequential therapy for treating rheumatoid arthritis in a subject, wherein the antibody comprises a heavy chain variable region (VH) comprising the sequence~~three complementarity determining regions (CDRs)~~ of SEQ ID NO:2 and a light chain variable region (VL) comprising the sequence~~three CDRs~~ of SEQ ID NO:3, wherein the subject was previously ineffectively treated for rheumatoid arthritis by administration of methotrexate.

2. The use of claim 1, wherein the antibody is to be administered at a dose of between 50 and 150 mg every week.

3. The use of ~~any of claims 1 to 2~~claim 1, wherein the antibody is to be administered at a dose of between 100 and 200 mg every two weeks.

4. The use of any of claims 1 ~~to~~ and 3, wherein the antibody is to be administered at a dose of 150 mg every two weeks or 200 mg every two weeks.

5. The use of claim 4, wherein the subject achieves at least a 20% improvement in the American College of Rheumatology (ACR) core set disease index after treatment~~.~~

~~6. The use of claim 5, wherein the subject achieves the improvement in the ACR core set disease index~~ after 12 weeks of treatment~~.~~ or

~~7. The use of claim 5, wherein the subject achieves the improvement in the ACR core set disease index~~ after 24 weeks of treatment.

~~8~~6. The use of claim 4, wherein the subject achieves at least a 50% improvement in the American College of Rheumatology (ACR) core set disease index after treatment~~.~~

~~9. The use of claim 8, wherein the subject achieves the improvement in the ACR core set disease index~~ after 12 weeks of treatment.

~~10~~7. The use of claim 4, wherein the subject achieves at least a 70% improvement in the American College of Rheumatology (ACR) core set disease index after treatment~~.~~

~~11. The use of claim 10, wherein the subject achieves the improvement in the ACR core set disease index~~ after 12 weeks of treatment.

~~12. The use of claim 4, wherein the subject achieves at least a 0.3 improvement in the Health Assessment Questionnaire Disability Index (HAQ-DI) after treatment.~~

~~13. The use of claim 12, wherein the subject achieves the improvement in HAQ-DI after 12 weeks of treatment.~~

~~14. The use of claim 4, wherein the subject achieves at least a decrease in Visual Acuity Score (VAS) of at least 30 after treatment as compared to baseline.~~

~~15. The use of claim 14, wherein the subject achieves the improvement in VAS after 12 weeks of treatment.~~

~~16. The use of claim 4, wherein the subject achieves at least a 1 mg/dL decrease in level of C-reactive protein (CRP) in blood sample and/or urine sample after treatment.~~

~~17. The use of claim 16, wherein the subject achieves the decrease in level of CRP after 12 weeks of treatment.~~

~~18. The use of claim 4, wherein the subject achieves an improvement in European League Against Rheumatism (EULAR) index after treatment.~~

~~19. The use of claim 18, wherein the subject achieves the improvement in EULAR index after 12 weeks of treatment.~~

~~20. The use of claim 4, wherein the subject achieves at least a 0.6 increase in disease activity score (DAS28) after treatment.~~

~~21. The use of claim 20, wherein the subject achieves the increase in DAS28 after 12 weeks of treatment.~~

~~22. The use of any one of claims 1-4, wherein the medicament further comprises methotrexate.~~

~~23~~8. The use of ~~claim 22~~any of claims 1 to 7, wherein the methotrexate is to be administered at a dose of between 6 to 25 mg per week.

~~24~~9. The use of any of claims 1 to ~~23~~8, wherein the antibody is sarilumab.

~~25~~10. The use of any of claims 1 to ~~24~~9, wherein the antibody is to be administered subcutaneously to the subject.